Analyst recommendations
LSE: Deutsche Bank’s research confirms his advice and maintains his neutral opinion on the stock.. The target price is lowered from GBX 7500 to GBX 7700.
Glaxosmithkline:
-
In a research note published by Keyur Parekh, Goldman Sachs advises its customers to buy the stock. The target price is unchanged and still at GBX 2060.
-
Analyst James Gordon from JP Morgan research gives the stock a Neutral rating. The target price continues to be set at GBX 1700.
ASML:
-
Achal Sultania from Credit Suisse retains his positive opinion on the stock with a Buy rating. The target price remains unchanged at EUR 375.
-
Goldman Sachs analyst Alexander Duval maintains his Buy rating on the stock. The target price remains unchanged at EUR 366.
-
Already positive, the research from Barclays and its analyst Andrew Gardiner still consider the stock as a Buy opportunity.. The target price is unchanged at EUR 375.
Scout24: UBS is less optimistic about the stock and is readjusting downwards his opinion. The broker’s analyst Richard Eary is now Neutral. The target price is lowered from EUR 69 to EUR 70.
Microsoft: In a research note published by Alex Zukin, RBC advises its customers to buy the stock. The target price is being increased from USD 200 to USD 240.
Total: Already positive, the research from JP Morgan and its analyst Christyan Malek still consider the stock as a Buy opportunity.. The target price is being increased from EUR 40 to EUR 42.
Shell: In a research note, JP Morgan analyst Christyan Malek has maintained his recommendation on the stock with a Neutral rating. The target price is increased from GBX 1650 to GBX 1700.
BP: In his latest research note, analyst Christyan Malek confirms his positive recommendation. The broker JP Morgan is keeping its Buy rating. Previously set at GBX 400, the target price has been raised to GBX 425.
ENI: Christyan Malek from JP Morgan retains his negative opinion on the stock with a Sell rating. The target price continues to be set at EUR 8.50.